University of Minnesota · Jan 2026
University of Minnesota highlighted a chemistry publication on YCT-529 and noted that the program was advancing in a phase 2a clinical trial in New Zealand.
YourChoice therapeutics is revolutionizing the contraceptive market…
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Clinical-stage biotechnology company developing hormone-free, oral male contraception; its lead asset YCT-529 is a reversible retinoic acid receptor-alpha (RAR-alpha) antagonist being evaluated in human clinical trials.
Primary product
YCT-529, a hormone-free oral male contraceptive pill
Founded
2018
Headquarters
Berkeley, California, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Reproductive health / contraceptive biopharma
Offices
Berkeley, CA (HQ)
San Francisco, California, United States
Berkeley, California, United States
Business model
clinical-stage biopharmaceutical development
Funding
Stage
Series A
Total raised
$15.7M
Latest round
Unattributed grant · Mar 2024
Latest amount
$500K
Mar 2024 · Male Contraceptive Initiative
Jul 2022 · Future Ventures
Mar 2019 · Y Combinator
People & investors
Work & culture
Product & market
Differentiators
- —First hormone-free male birth control pill candidate in human studies
- —Once-daily oral, non-hormonal mechanism
- —Reversible effect on sperm production in preclinical studies
- —No serious adverse events reported in early human studies
- —Only non-hormonal male birth control pill being evaluated in human studies
Technology
YCT-529
RAR-alpha antagonism
oral small-molecule contraception
reversible spermatogenesis inhibition
clinical-stage human trials
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
2.4K
Latest news
Business Wire · Jul 2025
The company announced publication of first-in-human safety data in Communications Medicine, including good tolerability and no meaningful effects on sexual desire or mood.
Reuters · Mar 2025
Reuters reported that YCT-529 was moving through early human studies and that the experimental hormone-free male pill had shown promising safety and reversibility signals in preclinical work.
Business Wire · Mar 2025
The company announced publication of preclinical data in Communications Medicine showing YCT-529 as a reversible, non-hormonal male contraceptive candidate with strong mouse and primate results.
BioSpace · Jun 2024
BioSpace covered completion of the first-in-human phase 1a study and the company’s presentation of early safety/tolerability results.
Jobs and careers at YourChoice Therapeutics
0 jobs at YourChoice Therapeutics
No open positions
Check back later for new openings